Skip to main content
Top
Published in: BMC Cancer 1/2001

Open Access 01-12-2001 | Research article

Return to fertility after extended chemical castration with a GnRH antagonist

Authors: Janusz W Kostanski, Ge Jiang, Bhas A Dani, Santos B Murty, Wei Qiu, Bruce Schrier, B C Thanoo, Patrick P DeLuca

Published in: BMC Cancer | Issue 1/2001

Login to get access

Abstract

Background

Antagonistic analogues of GnRH for the treatment of prostate cancer may be used clinically in persons for whom return to fertility after such treatment is important or desirable. The purpose of this study was, therefore, to evaluate the effects of a long term treatment with orntide, a GnRH antagonist, on testosterone levels and fertility in male rats.

Methods

Two groups of male rats received either 120-day orntide microspheres (8.8 mg orntide/kg/120 days) or vehicle alone (control group). Serum orntide and testosterone levels in both groups were monitored at certain intervals for 9 months from the initiation of treatment. After recovery of normal serum testosterone levels in the treated animals, each rat was housed with two proven breeder, but drug-naive, females.

Results

All mates of treated rats achieved pregnancy as rapidly as the mates of control rats although two of the control rats did not sire a litter with either female and one sired only one litter. The mean size of the litters of treated (12.3 offspring per litter) and control (10.6 offspring per litter) were similar. All offspring were grossly normal morphologically and behaviorally during the time to weaning.

Conclusions

These results suggest that lack of fertility due to testosterone suppression is reversible after cessation of treatment with this GnRH antagonist.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kirby RS: Recent advances in the medical management of prostate cancer. Br J Clin Pract. 1996, 50: 88-93.PubMed Kirby RS: Recent advances in the medical management of prostate cancer. Br J Clin Pract. 1996, 50: 88-93.PubMed
2.
go back to reference Winkel CA: Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs. Postgrad Med. 1994, 95: 111-118.PubMed Winkel CA: Gonadotropin-releasing hormone agonists. Current uses for these increasingly important drugs. Postgrad Med. 1994, 95: 111-118.PubMed
3.
go back to reference Moul JW: Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt). 1998, 12: 499-505. Moul JW: Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt). 1998, 12: 499-505.
4.
go back to reference Cersosimo RJ, Carr D: Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996, 53: 381-396.PubMed Cersosimo RJ, Carr D: Prostate cancer: current and evolving strategies. Am J Health Syst Pharm. 1996, 53: 381-396.PubMed
5.
go back to reference Popov I, Jelic S, Radosavljevic D, Nikolic-Tomasevic Z: Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer-speculations about possible role of the monoamine system. Neoplasma. 1997, 44: 308-313.PubMed Popov I, Jelic S, Radosavljevic D, Nikolic-Tomasevic Z: Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer-speculations about possible role of the monoamine system. Neoplasma. 1997, 44: 308-313.PubMed
6.
go back to reference Weinbauer GF, Nieschlang E: LHRH Antagonists: State of the Art and Future Perspectives. Recent Results Cancer Research. 1992, 124: 113-136.CrossRef Weinbauer GF, Nieschlang E: LHRH Antagonists: State of the Art and Future Perspectives. Recent Results Cancer Research. 1992, 124: 113-136.CrossRef
7.
go back to reference Chen HF, Jeung EB, Stephenson M, Leung PCK: Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro . J Clin Endocrinol Metab. 1999, 84: 743-750.PubMed Chen HF, Jeung EB, Stephenson M, Leung PCK: Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro . J Clin Endocrinol Metab. 1999, 84: 743-750.PubMed
8.
go back to reference Koppan M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate. 1999, 38: 151-158. 10.1002/(SICI)1097-0045(19990201)38:2<151::AID-PROS9>3.0.CO;2-#.CrossRefPubMed Koppan M, Nagy A, Schally AV, Plonowski A, Halmos G, Arencibia JM, Groot K: Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate. 1999, 38: 151-158. 10.1002/(SICI)1097-0045(19990201)38:2<151::AID-PROS9>3.0.CO;2-#.CrossRefPubMed
9.
go back to reference Ohta H, Sakamoto H, Satoh K: In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett. 1998, 134: 111-118. 10.1016/S0304-3835(98)00270-5.CrossRefPubMed Ohta H, Sakamoto H, Satoh K: In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinum. Cancer Lett. 1998, 134: 111-118. 10.1016/S0304-3835(98)00270-5.CrossRefPubMed
10.
go back to reference Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A: Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Treat. 1996, 40: 129-139.CrossRefPubMed Szepeshazi K, Schally AV, Halmos G, Szoke B, Groot K, Nagy A: Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors. Breast Cancer Res Treat. 1996, 40: 129-139.CrossRefPubMed
11.
go back to reference Troskie B, Illing N, Rumbak E, Sun YM, Hapgood J, Sealfon S, Conklin D, Millar R: Identification of three putative GnRH receptor subtypes in vertebrates. Gen Comp Endocrinol. 1998, 112: 296-302. 10.1006/gcen.1998.7156.CrossRefPubMed Troskie B, Illing N, Rumbak E, Sun YM, Hapgood J, Sealfon S, Conklin D, Millar R: Identification of three putative GnRH receptor subtypes in vertebrates. Gen Comp Endocrinol. 1998, 112: 296-302. 10.1006/gcen.1998.7156.CrossRefPubMed
12.
go back to reference Kostanski JW, Dani BA, Schrier B, DeLuca PP: Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. Pharm Res. 2000, 17: 445-450. 10.1023/A:1007581004844.CrossRefPubMed Kostanski JW, Dani BA, Schrier B, DeLuca PP: Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats. Pharm Res. 2000, 17: 445-450. 10.1023/A:1007581004844.CrossRefPubMed
13.
go back to reference Kostanski JW, Thanoo BC, DeLuca PP: Preparation, characterization and in vitro evaluation of 1- and 4-month controlled release Orntide PLA and PLGA microspheres. Pharm Develop Tech. 2000, 5: 585-596. 10.1081/PDT-100102043.CrossRef Kostanski JW, Thanoo BC, DeLuca PP: Preparation, characterization and in vitro evaluation of 1- and 4-month controlled release Orntide PLA and PLGA microspheres. Pharm Develop Tech. 2000, 5: 585-596. 10.1081/PDT-100102043.CrossRef
Metadata
Title
Return to fertility after extended chemical castration with a GnRH antagonist
Authors
Janusz W Kostanski
Ge Jiang
Bhas A Dani
Santos B Murty
Wei Qiu
Bruce Schrier
B C Thanoo
Patrick P DeLuca
Publication date
01-12-2001
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2001
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-1-18

Other articles of this Issue 1/2001

BMC Cancer 1/2001 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine